Association between Benign Prostatic Hyperplasia and Neutrophil-Lymphocyte Ratio, an Indicator of Inflammation and Metabolic Syndrome

Abstract

Aim: There is a large body of evidence of clinical studies regarding the relation between metabolic syndrome (MetS) and benign prostatic hyperplasia (BPH)-related lower urinary tract symptoms (LUTS) in men. A possible link between inflammation and these 2 clinical entities has also been proposed. Here, we aimed at evaluating the role of neutrophil-lymphocyte ratio (NLR), an indicator of inflammation and MetS, in the pathogenesis of LUTS and other BPH-related parameters. Method: We evaluated 244 patients with benign prostate hyperplasia admitted to our outpatient clinic between January 2014 and June 2015. NLR was calculated from the peripheral blood sample for all patients. Patients' anthropometric characteristics, serum lipid levels, waist circumferences, total prostate-specific antigen (PSA) and testosterone values, prostate volumes, max values and International Prostate Symptom Score (IPSS) were recorded. All statistical analyses were conducted by SPSS version 17.0 package program, and p value <0.05 was chosen as the criterion for statistical significance. Results: There was statistical significance between NLR and patients with severe IPSS score (>20) and over age 60 years (p = 0.02). Patients younger than 60 years had statistical significance between NLR and PSA <2.5 ng/dl (p = 0.004). When body mass index was selected, there was statistical significance between prostate volume <35 ml (p = 0.009) and age >60 years (p = 0.028). If 60 years of age was selected as cut-off value, there is statistical significance between age and severe IPSS, and in terms of mild erectile dysfunction, PSA >2.5 ng/dl, and prostate volume >35 ml. Conclusion: We found positive correlation between NLR and severe symptoms and progression of BPH. In this manner, anti-inflammatory therapy could contribute to the medical treatment of BPH. Higher NLR may be a candidate marker for severity of symptoms in BPH patients.

Clinical optimal dose of solifenacin succinate for�nursing patients after transurethral resection of the prostate during the perioperative period

“…Bishr et al (22) also investigated the medical management of benign prostatic hyperplasia in a population-based study. Assessing inflammation and the most common adverse events is essential for nursing patients with benign prostate hyperplasia during the perioperative period (23,24). This study focused on the clinical significance of different dosages of SOL for patients with benign prostate hyperplasia during perioperative period.…”

Impact of Testosterone Deficiency and Testosterone Therapy on Lower Urinary Tract Symptoms in Men with Metabolic Syndrome

“…Central obesity and WC, components of Met S, have been associated with increased risk for BPH and LUTS [1415161718192021222324252627282930]. However, central obesity may adversely impact LUTS independent of the prostate growth, as demonstrated by changes in severity of LUTS in men after prostatectomy [31323334].…”

Androgen Deficiency and Progression of Benign Prostatic Hyperplasia in Patients With Metabolic Syndrome: Is There Any Controversy? (A Literature Review)

“…Иссле-дуя взаимосвязь хронического системного воспаления, развития ДГПЖ и МС, K. Ozer и соавт. [67] установи-ли, что отношение нейтрофилы / лимфоциты в пери-ферической крови, которое является маркером сис-темной воспалительной реакции, оказалось выше у больных с более высоким индексом IPSS, при возра-сте старше 60 лет, большей массе тела и объеме ПЖ >35 см 3 , что, по мнению авторов, указывает на целесо-образность включения противовоспалительной тера-пии в схему лечения больных ДГПЖ с МС.…”